Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Tauriga Sciences's Enterprise Value is $0.00 Mil.
Tauriga Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2021 was $-5.01 Mil. Therefore, Tauriga Sciences's EV-to-EBIT ratio for today is 0.00.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Tauriga Sciences's Enterprise Value is $0.00 Mil.
Tauriga Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2021 was $-5.01 Mil. Therefore, Tauriga Sciences's EV-to-EBITDA ratio for today is 0.00.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Tauriga Sciences's Enterprise Value is $0.00 Mil.
Tauriga Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2021 was $0.31 Mil. Therefore, Tauriga Sciences's EV-to-Revenue ratio for today is 0.00.
Tauriga Sciences Enterprise Value Historical Data
The historical data trend for Tauriga Sciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Tauriga Sciences's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, Tauriga Sciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tauriga Sciences's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tauriga Sciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Tauriga Sciences's Enterprise Value falls into.
Tauriga Sciences Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Tauriga Sciences's Enterprise Value for the fiscal year that ended in Mar. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tauriga Sciences (OTCPK:TAUG) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Tauriga Sciences's current Enterprise Value is $0.00 Mil.
Tauriga Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.01 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Tauriga Sciences's current Enterprise Value is $0.00 Mil.
Tauriga Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.01 Mil.
Tauriga Sciences's current Enterprise Value is $0.00 Mil.
Tauriga Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tauriga Sciences Enterprise Value Related Terms
Thank you for viewing the detailed overview of Tauriga Sciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Tauriga Sciences (Tauriga Sciences) Business Description
Tauriga Sciences Inc is a revenue-generating company that operates through the development, distribution, and licensing of proprietary products as well as evaluation of potential acquisition opportunities. The firm has entered into the cannabidiol (or CBD) infused chewing gum product business. This CBD-infused chewing gum product has been branded under Tauri-Gum. The company commenced sales of Peach-Lemon and Black Currant CBG Gum. It operates in two segments: Tauri-gum division consists of all retail, wholesale, and e-commerce product sales of CBD/CBG Tauri-Gum, Tauri-Gummies, and other CBD/CBG products. Pharma segment includes research and development of the company's FDA IND application for Phase II Trial of its proposed pharmaceutical-grade version of Tauri-Gum.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TAUG has been successfully added to your 